General Information of Drug Transporter (DT)
DT ID DTD0006 Transporter Info
Gene Name SLC22A2
Transporter Name Organic cation transporter 2
Gene ID
6582
UniProt ID
O15244
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13.3 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT2
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 8.7 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Quinine inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 3.4 microM) [5]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Quinine inhibits the transportation of YM155 by SLC22A2 (IC50 = 11 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Quinine inhibits the activity of SLC22A2 [7]
Cell System Xenopus laevis oocytes-OCT2
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 120 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Cimetidine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 373 microM) [8]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Cimetidine inhibits the transportation of YM155 by SLC22A2 (IC50 = 110 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Cimetidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A2 [9]
Affected Drug/Substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition
DT Modulation Cimetidine inhibits the activity of SLC22A2 [10], [11]
Exogenous Factor Ranitidine Approved Drug
DT Modulation Ranitidine inhibits the transportation of Cimetidine by SLC22A2 (Ki = 79 microM) [12]
Affected Drug/Substrate Cimetidine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Ranitidine inhibits the transportation of Famotidine by SLC22A2 (Ki = 30.5 microM) [12]
Affected Drug/Substrate Famotidine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1617 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 76 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 521 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 398 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 289 microM) [13]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Metformin inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 1380 microM) [13]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Fenamiphos Natural Product
DT Modulation Fenamiphos inhibits the transportation of Dopamine by SLC22A2 (IC50 = 2.8 microM) [14]
Affected Drug/Substrate Dopamine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Fenamiphos inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 6.9 microM) [14]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Phosmet Natural Product
DT Modulation Phosmet inhibits the transportation of Dopamine by SLC22A2 (IC50 = 3.6 microM) [14]
Affected Drug/Substrate Dopamine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Phosmet inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 7.9 microM) [14]
Affected Drug/Substrate Rhodamine 123 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Piperine Natural Product
DT Modulation Piperine inhibits the transportation of Metformin by SLC22A2 (IC50 = 3.727 microM) [15]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-OCT2
DT Modulation Piperine inhibits the transportation of Serotonin by SLC22A2 (IC50 = 5.4 microM) [15]
Affected Drug/Substrate Serotonin Modulation Type Inhibition
Cell System Madin darby canine kidney strain cell line (MDCK)-OCT2
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 28.4 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Amantadine inhibits the transportation of YM155 by SLC22A2 (IC50 = 45.9 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Carvedilol Approved Drug
DT Modulation Carvedilol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 63 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Carvedilol inhibits the activity of SLC22A2 (IC50 = 3.6 microM) [17]
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Clonidine Approved Drug
DT Modulation Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 16 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Diphenhydramine Approved Drug
DT Modulation Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 21 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Flurazepam Approved Drug
DT Modulation Flurazepam inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 60 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Flurazepam inhibits the activity of SLC22A2 [21]
Exogenous Factor Mexiletine Approved Drug
DT Modulation Mexiletine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 55 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Mexiletine inhibits the activity of SLC22A2 [21]
Exogenous Factor Phenformin Drug Withdrawn
DT Modulation Phenformin inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 54 microM) [13]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Phenformin inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 111 microM) [13]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Propranolol Approved Drug
DT Modulation Propranolol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 229 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Propranolol inhibits the activity of SLC22A2 [21]
Exogenous Factor Tetraethylammonium Investigative Drug
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 222 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 189.2 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT2
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 85 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
DT Modulation Verapamil inhibits the transportation of YM155 by SLC22A2 (IC50 = 13.4 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Decynium 22 Investigative Drug
DT Modulation Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 0.1 microM) [5]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 13.8 microM) [8]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor N-methylpyridinium Drug in Preclinical Test
DT Modulation N-methylpyridinium inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 2.4 microM) [5]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation N-methylpyridinium inhibits the transportation of YM155 by SLC22A2 (IC50 = 4.42 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 50 microM) [5]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
DT Modulation Procainamide inhibits the transportation of YM155 by SLC22A2 (IC50 = 91.9 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Telaprevir Approved Drug
DT Modulation Telaprevir inhibits the activity of SLC22A2 (IC50 = 0.0064 microM) [18]
DT Modulation Telaprevir inhibits the activity of SLC22A2 [22]
Exogenous Factor Dolutegravir Approved Drug
DT Modulation Dolutegravir inhibits the transportation of Metformin by SLC22A2 [19]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Madin Darby canine kidney strain II (MDCKII) cells-OCT2
DT Modulation Dolutegravir inhibits the activity of SLC22A2 [20]
Exogenous Factor Estradiol Approved Drug
DT Modulation Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 > 30 microM) [23]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Phenoxybenzamine Approved Drug
DT Modulation Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 4.9 microM) [23]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Progesterone Approved Drug
DT Modulation Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 26.7 microM) [23]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor DX-619 Discontinued Drug
DT Modulation DX-619 inhibits the transportation of Creatinine by SLC22A2 (Ki = 0.94 microM) [24]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Grepafloxacin Approved Drug
DT Modulation Grepafloxacin inhibits the transportation of Creatinine by SLC22A2 (Ki = 10.4 microM) [24]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Crizotinib Approved Drug
DT Modulation Crizotinib inhibits the transportation of Creatinine by SLC22A2 (IC50 = 1.58 +/- 0.24 microM) [25]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Famotidine Approved Drug
DT Modulation Famotidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 114 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 6 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Fenfluramine Drug Withdrawn
DT Modulation Fenfluramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Doxepin Approved Drug
DT Modulation Doxepin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Amitriptyline Approved Drug
DT Modulation Amitriptyline inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Chlorpromazine Approved Drug
DT Modulation Chlorpromazine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor YM155 Drug in Phase 2 Trial
DT Modulation YM155 inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15.9 microM) [6]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Propafenone Approved Drug
DT Modulation Propafenone inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 25 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Sibutramine Approved Drug
DT Modulation Sibutramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 29 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Atropine Approved Drug
DT Modulation Atropine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 39 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Tamoxifen Approved Drug
DT Modulation Tamoxifen inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Flecainide Approved Drug
DT Modulation Flecainide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 191 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Mefloquine Approved Drug
DT Modulation Mefloquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 204 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Disopyramide Approved Drug
DT Modulation Disopyramide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 324 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Butylscopolamine Approved Drug
DT Modulation Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 764 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Chloroquine Approved Drug
DT Modulation Chloroquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1096 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Trimethoprim Approved Drug
DT Modulation Trimethoprim inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1318 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Etilefrine Drug Withdrawn
DT Modulation Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 4009 microM) [4]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Memantine Approved Drug
DT Modulation Memantine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 7.3 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Dextroamphetamine Approved Drug
DT Modulation Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 10.5 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Dizocilpine Discontinued Drug
DT Modulation Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 21.5 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Ketamine Approved Drug
DT Modulation Ketamine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 22.7 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Phencyclidine Investigative Drug
DT Modulation Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 24.9 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Cocaine Approved Drug
DT Modulation Cocaine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 113 microM) [16]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Pentamidine Approved Drug
DT Modulation Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10.6 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT2
Exogenous Factor Antiparasitics Discontinued Drug
DT Modulation Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 182 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT2
Exogenous Factor Cyclopiazonic acid Mycotoxins
DT Modulation Cyclopiazonic acid inhibits the transportation of Organic cation by SLC22A2 (IC50 > 1000 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Patulin Mycotoxins
DT Modulation Patulin inhibits the transportation of Organic cation by SLC22A2 (IC50 > 1000 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Citreoverdine Natural Product
DT Modulation Citreoverdine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Citrioveridine Mycotoxins
DT Modulation Citrioveridine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Zearalenone Mycotoxins
DT Modulation Zearalenone inhibits the transportation of Organic cation by SLC22A2 (IC50 = 24.8 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Alpha-zearalenol Mycotoxins
DT Modulation Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A2 (IC50 = 34.3 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Gliotoxin Mycotoxins
DT Modulation Gliotoxin inhibits the transportation of Organic cation by SLC22A2 (IC50 = 117 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Aflatoxin B1 Mycotoxins
DT Modulation Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A2 (IC50 = 121 microM) [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Fumonisin B1 Mycotoxins
DT Modulation Fumonisin B1 inhibits the transportation of Organic cation by SLC22A2 [26]
Affected Drug/Substrate Organic cation Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Decitabine Approved Drug
DT Modulation Decitabine inhibits DNA methyltransferase, which then enhances Oxaliplatin's transportation via downregulating the hypermethylation in SLC22A2's promoter [27]
Affected Drug/Substrate Oxaliplatin Modulation Type Inducer
Cell System Human renal cell carcinoma cells (RCC)
Exogenous Factor Vorinostat Approved Drug
DT Modulation Vorinostat inhibits histone deacetylase, which then enhances Oxaliplatin's transportation via increasing the histone acethylation level of SLC22A2 (IC50 = 4.69 microM) [28]
Affected Drug/Substrate Oxaliplatin Modulation Type Inducer
Cell System Human renal cell carcinoma cells (RCC)
Exogenous Factor Aconitine Biotoxin
DT Modulation Aconitine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 59.2 microM) [29]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System The Proximal Tubule (S2) Cells-OCT2
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 16 microM) [5]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor Pyridine Drug in Phase 4 Trial
DT Modulation Pyridine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 790 microM) [30]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT2
Exogenous Factor Tetramethrin Natural Product
DT Modulation Tetramethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 11.2 microM) [31]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Allethrin Natural Product
DT Modulation Allethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 42.6 microM) [31]
Affected Drug/Substrate Verapamil Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Corticosterone Investigative Drug
DT Modulation Corticosterone inhibits the transportation of YM155 by SLC22A2 (IC50 = 5.35 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Prazosin Approved Drug
DT Modulation Prazosin inhibits the transportation of YM155 by SLC22A2 (IC50 = 80.4 microM) [6]
Affected Drug/Substrate YM155 Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the activity of SLC22A2 (IC50 = 12.5 microM) [32]
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Testosterone Approved Drug
DT Modulation Testosterone inhibits the activity of SLC22A2 (IC50 = 3 microM) [33]
Exogenous Factor Cetirizine Approved Drug
DT Modulation Cetirizine inhibits the transportation of Tetraethylammonium by SLC22A2 [34]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor Pilsicainide Approved Drug
DT Modulation Pilsicainide inhibits the transportation of Tetraethylammonium by SLC22A2 [34]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Oocytes-OCT2
Exogenous Factor Quercetin Approved Drug
DT Modulation Quercetin induces the transportation of Tetraethylammonium by SLC22A2 [35]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles
Exogenous Factor Nicotine Approved Drug
DT Modulation Nicotine inhibits the transportation of Tetraethylammonium by SLC22A2 [36]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Vitamin B1 Approved Drug
DT Modulation Vitamin B1 inhibits the transportation of Tetraethylammonium by SLC22A2 [36]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Genistein Drug in Phase 2 Trial
DT Modulation Genistein induces the transportation of Tetraethylammonium by SLC22A2 [35]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles
Exogenous Factor Naringenin Drug in Phase 1 Trial
DT Modulation Naringenin induces the transportation of Tetraethylammonium by SLC22A2 [35]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles
Exogenous Factor Acecainide Discontinued Drug
DT Modulation Acecainide inhibits the transportation of Tetraethylammonium by SLC22A2 [36]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT2
Exogenous Factor Green tea Natural Product
DT Modulation Green tea inhibits the transportation of Metformin by SLC22A2 [37]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-OCT2
Exogenous Factor Metoprolol Approved Drug
DT Modulation Metoprolol inhibits the transportation of Cimetidine by SLC22A2 [38]
Affected Drug/Substrate Cimetidine Modulation Type Inhibition
Exogenous Factor Oxprenolol Approved Drug
DT Modulation Oxprenolol inhibits the transportation of Cimetidine by SLC22A2 [38]
Affected Drug/Substrate Cimetidine Modulation Type Inhibition
Exogenous Factor Budesonide Approved Drug
DT Modulation Budesonide inhibits the activity of SLC22A2 [39]
Exogenous Factor Cisplatin Approved Drug
DT Modulation Cisplatin inhibits the activity of SLC22A2 [40], [41]
Exogenous Factor Dexamethasone Approved Drug
DT Modulation Dexamethasone induces the activity of SLC22A2 [42]
Exogenous Factor Diazepam Approved Drug
DT Modulation Diazepam inhibits the activity of SLC22A2 [29]
Exogenous Factor Haloperidol Approved Drug
DT Modulation Haloperidol inhibits the activity of SLC22A2 [29]
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of SLC22A2 [43]
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the activity of SLC22A2 [43]
Exogenous Factor Lidocaine Approved Drug
DT Modulation Lidocaine inhibits the activity of SLC22A2 [29]
Exogenous Factor Malathion Approved Drug
DT Modulation Malathion inhibits the activity of SLC22A2 [29]
Exogenous Factor Mianserin Approved Drug
DT Modulation Mianserin inhibits the activity of SLC22A2 [29]
Exogenous Factor Plazomicin Approved Drug
DT Modulation Plazomicin inhibits the activity of SLC22A2 [44]
Exogenous Factor Triazolam Approved Drug
DT Modulation Triazolam inhibits the activity of SLC22A2 [29]
Exogenous Factor Vancomycin Approved Drug
DT Modulation Vancomycin inhibits the activity of SLC22A2 [45]
Exogenous Factor Chlorpyrifos Natural Product
DT Modulation Chlorpyrifos inhibits the activity of SLC22A2 [29]
Exogenous Factor Fenitrothion Environmental toxicant
DT Modulation Fenitrothion inhibits the activity of SLC22A2 [29]
References
1 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
2 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
3 Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48.
4 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
5 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
6 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
7 Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem. 2001 Nov 9;276(45):41611-9.
8 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
9 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011 Jul 14;54(13):4548-58.
10 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
11 The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem. 2002 Jun 21;277(25):22491-6.
12 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
13 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
14 Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Xenobiotica. 2019 Mar;49(3):363-374.
15 Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:90-8.
16 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
17 Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res. 2018 Sep 6;35(11):204.
18 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
19 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
20 Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. Antimicrob Agents Chemother. 2014;58(3):1294-301.
21 Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8.
22 eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int. 2015 Jan;35(1):71-8.
23 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
24 Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011 Jan;89(1):81-8.
25 Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2. J Pharm Sci. 2017 Sep;106(9):2899-2903.
26 Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43.
27 Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med. 2016 Jul 20;8(348):348ra97.
28 Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma. Epigenetics. 2019 May 15:1-13.
29 Human organic cation transporter 2 (hOCT2): Inhibitor studies using S2-hOCT2 cells. Toxicology. 2013 Aug 9;310:98-103.
30 Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos. 2011 Sep;39(9):1755-61.
31 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
32 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
33 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51.
34 Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther. 2006 Apr;79(4):389-96.
35 Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica. 2008 Dec;38(12):1536-50.
36 cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10.
37 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
38 The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9.
39 Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005 Jul;33(1):79-88.
40 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
41 Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011 Mar 1;81(5):563-8.
42 Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther. 2001 Oct;299(1):392-8.
43 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
44 No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Jan 3.
45 JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicol Lett. 2018 Oct 1;295:195-204.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.